Loading data...
MEDICOLAB Inc.
CEO
Kazuhiro Ikumi
Development of medical AI software capable of detecting and monitoring Parkinsonian syndromes that were previously undetectable via MRI. Compared t...
Recent News & PR
Summary
Message to Participants
Detailed Information
Development of medical AI software capable of detecting and monitoring Parkinsonian syndromes that were previously undetectable via MRI. Compared to conventional examinations, hospitals benefit from a cost reduction of ¥55k JPY per case, a reduction in examination time from 3.5 hours to 10 minutes, and the ability to conduct exams without radiation exposure.
Unfair Advantage & Strengths
N/A
Competitors
N/A
Company Profile
事業カテゴリ
Healthcare / Biotech
本社所在地
愛知県名古屋市西区
設立日
2018年06月12日
資本金
N/A
Employee Count
1
Industry Outlook & Trends for MEDICOLAB Inc.
Driven by aging populations and rising healthcare costs, the healthcare and biotech market where MEDICOLAB Inc. operates is growing globally. Telemedicine, digital health via wearables, AI-driven drug discovery, and gene therapy are advancing rapidly. The industry is shifting from treatment to prevention, increasing demand for highly personalized health solutions like those developed by MEDICOLAB Inc..
🔒
VPO Investor Pro Features
You are viewing a basic startup profile. Create a free account to access the dashboard. You can also upgrade to the "Investor Pro" plan to unlock full access to the following premium databases and features:
🎬
Elevator & Full Pitch Video
Watch full presentations with English/Japanese subtitles.
📊
AI Quick Report & Valuation
Get AI-driven assessment scores on market, product, and traction.
📅
Priority Challenges & Hiring
Access core corporate bottlenecks and current hiring plans.
📝
Full Transcripts
Read full pitch dialogue in both English and Japanese.
📈
Financials & Exit Strategy
Unlock IPO/M&A timelines and debt/equity plans.
👥
Advisors & Key Members
View internal team details and advisory board configurations.